TLR7 and neoplasm: Here we report the development of an X-ray-activated nanomotor, GM-R848, comprising an iron carbonyl (FeCO) prodrug framework encapsulating the TLR7 agonist resiquimod (R848), designed for efficient tumor cell elimination and immune activation.